Redpoint Investment Management’s Royalty Pharma RPRX Stock Holding History

Redpoint Investment Management’s Portfolio RPRX Stock Details RPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	$376K	Hold	9,366	–	–	0.06%	386
2022 Q2	$394K	Hold	9,366	–	–	0.05%	429
2022 Q1	$365K	Buy	9,366 +2,669	+40%	+$105K	0.04%	510
2021 Q4	$267K	Hold	6,697	–	–	0.02%	593
2021 Q3	$242K	Hold	6,697	–	–	0.02%	603
2021 Q2	$275K	Buy	+6,697	New	+$285K	0.02%	598

Other funds holding RPRX

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

SGA

Siguler Guff Advisers New York $56.1M AUM 46.63% 1-Year Est. Return

Redpoint Investment Management's RPRX Position: Q3 2022 in Review

Redpoint Investment Management held its Royalty Pharma (RPRX) position steady in Q3 2022 at 9,366 shares worth $376K. The position accounts for 0.06% of the portfolio, ranked #386.

Redpoint Investment Management first reported a position in RPRX in Q2 2021 and has held it in 6 quarters since. The position peaked at $394K in Q2 2022. 319 funds tracked by Wall St. Rank hold RPRX as of Q3 2022.

Redpoint Investment Management held 9,366 shares of Royalty Pharma worth $376K as of Q3 2022.
Redpoint Investment Management left its Royalty Pharma share count unchanged in Q3 2022.
Royalty Pharma made up 0.06% of Redpoint Investment Management's portfolio in Q3 2022, its #386 holding.
Redpoint Investment Management first reported a position in Royalty Pharma in Q2 2021 and has held it in 6 quarters since.
Redpoint Investment Management's Royalty Pharma position peaked at $394K in Q2 2022.
319 funds tracked by Wall St. Rank held Royalty Pharma as of Q3 2022.

Based on Redpoint Investment Management's 13F filing for Q3 2022, filed 14 Oct 2022.